The combination of BRAF and MEK inhibitors (vemurafenib and cobimetinib) was approved in 2015 for treatment of patients with unresectable or metastatic melanoma who harbor a BRAF V600E or V600K mutation [77]. Here, BRAF is linked to metastatic melanoma.